Induction therapy

DRUG11 trials

Sponsors

Brooke Army Medical Center, National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), West German Study Group, Novartis Pharmaceuticals

Conditions

Breast CancerCarcinoma, Non-Small-Cell LungChronic Kidney Disease (CKD)End Stage Renal Disease (ESRD)Engraftment SyndromeGraft-Versus-Host DiseaseHead and Neck Squamous Cell Carcinoma (HNSCC)Hemodialysis

Phase 2

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

CompletedNCT00923845

National Cancer Institute (NCI)Engraftment Syndrome, Graft-Versus-Host Disease, Renal Cell Carcinoma

Start: 2008-03-01End: 2017-06-22Updated: 2017-09-29

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

CompletedNCT01781338

West German Study GroupBreast Cancer

Start: 2012-05-31End: 2025-01-15Target: 4936Updated: 2025-02-27

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

WithdrawnNCT04849377

Icahn School of Medicine at Mount SinaiHead and Neck Squamous Cell Carcinoma (HNSCC), Human Papillomavirus (HPV)

Start: 2022-06-14End: 2022-06-14Updated: 2022-07-07

Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

RecruitingNCT06793553

Japan Breast Cancer Research GroupMetastatic Breast Cancer

Start: 2024-09-13End: 2028-09-30Target: 106Updated: 2025-01-30

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

RecruitingNCT07149857

Janssen Research & Development, LLCMultiple Myeloma

Start: 2025-10-03End: 2029-04-06Target: 60Updated: 2026-03-13

Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

RecruitingNCT07165769

Institute of Hematology & Blood Diseases Hospital, ChinaSplenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN

Start: 2025-09-04End: 2029-12-31Target: 47Updated: 2025-12-18

Phase 4

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

CompletedNCT00207363

Brooke Army Medical CenterHepatitis C

Start: 2002-02-28End: 2010-01-31Updated: 2012-02-14

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

CompletedNCT01950819

Novartis PharmaceuticalsChronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hemodialysis +2

Start: 2013-12-03End: 2018-01-17Updated: 2019-01-30

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients

CompletedNCT03644485

Astellas Pharma China, Inc.Kidney Transplant

Start: 2018-10-21End: 2022-07-15Updated: 2024-10-31

Unknown Phase

Alloantibodies in Pediatric Heart Transplantation

TerminatedNCT01005316

National Institute of Allergy and Infectious Diseases (NIAID)Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients

Start: 2010-01-31End: 2014-12-31Updated: 2017-04-20

Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option

RecruitingNCT04926584

Klinikum EsslingenCarcinoma, Non-Small-Cell Lung

Start: 2017-12-15End: 2027-12-31Target: 50Updated: 2022-08-16

Related Papers

Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study

BMJ Open2021-10-0140 citations

Everolimus‐facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2‐year results from the subgroup analysis of the TRANSFORM study

Clinical Transplantation2021-07-037 citations

EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR REGIMEN VERSUS MYCOPHENOLIC ACID WITH STANDARD CALCINEURIN REGIMEN IN ASIAN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: TWO-YEAR RESULTS FROM THE SUBGROUP ANALYSIS OF TRANSFORM STUDY

Transplantation2020-08-281 citations

Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study

Expert Opinion on Drug Safety2020-07-077 citations

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.

2019-07-01106 citations

Efficacy and Safety of Everolimus with Reduced-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients

Transplantation2018-07-014 citations

Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor

Transplantation2018-07-012 citations

Effects of the De Novo use of Everolimus with Reduced Calcineurin Inhibitor on Wound Healing Events in the TRANSFORM Study

Transplantation2018-07-012 citations

TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation

Open Access Journal of Clinical Trials2014-06-0126 citations

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.

2013-08-1985 citations